Patheon Completes Expansion at Greenville Facility
PTSM: Pharmaceutical Technology Sourcing and Management
The company invested approximately $26 million to update its sterile pharmaceutical and development service suites.
On May 8, 2017, Patheon announced that it has completed an expansion project at its Greenville, NC manufacturing site. The company invested approximately $26 million to update its sterile pharmaceutical development service (PDS) suite and to build an integrated sterile PDS suite that is compliant with regulatory authorities. The PDS suites provide 7000-square-feet in GMP sterile manufacturing space.
The newly built PDS suite will manufacture sterile liquid and lyophilized drug products. It features freeze dryers and a fully integrated filling line fitted with a restricted access barrier system for sterile drug products. The company has made the investment in disposable manufacturing in this suite eliminating the need for cleaning verification for liquid filling, reducing set up time/product losses, and enhancing sterility assurance. This suite is fully integrated and designed for products in clinical development with the ability to scale up to much larger batch sizes.
Patheon will be attending the CPhI North America conference in Philadelphia, PA from May 16–18, 2017. The company is hosting a panel session at the conference on May 16, 2017.
Source: Patheon
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
